spec sheet10 rows
PMMA (para-methoxymethamphetamine) is the N-methylated homolog of PMA and shares its hazardous profile as a serotonin releaser with monoamine oxidase inhibitory activity. Like PMA it comes on slowly and carries a high risk of fatal hyperthermia, and the two are frequently found together in tablets misrepresented as MDMA. Preclinical work shows lasting serotonergic effects on brain serotonin markers, while human studies of fatal cases have detailed its metabolism and a pronounced dependence on CYP2D6 genotype, which may contribute to variable and unpredictable toxicity between individuals. PMMA has been implicated in epidemic clusters of ecstasy-related deaths, including a notable wave in Norway, and is considered among the substances most strongly linked to such fatalities.
- Mild stimulation
- Modest warmth
- N-methyl PMA relative; strong serotonergic toxicity
- Fatal hyperthermia risk
- Serotonin toxicity
- Cardiovascular strain and seizures
Mechanism
PMMA releases and, more weakly, and , and also inhibits monoamine oxidase. The serotonin-heavy release combined with reduced breakdown produces strong serotonergic toxicity and hyperthermia while giving only modest desirable effects, so the toxic dose is close to the felt dose.
receptor fingerprint
transporterReleaser
Monoamine oxidaseInhibitor
Releaser
Safetyrisks and cautions, not medical advice
PMMA's slow onset encourages redosing into a toxic range, and its serotonin release plus MAOI activity make fatal hyperthermia and serotonin syndrome real risks. It is especially dangerous with other serotonergic drugs, stimulants, or MAOIs. Numerous deaths have been attributed to PMMA-adulterated ecstasy. Not medical advice.
Subjective profileweighing the evidence above
There is no safe way to take this. The slow onset invites redosing, and serotonin release plus MAO inhibition drives fatal hyperthermia; it has been behind clusters of deaths in tablets sold as MDMA. Its own effects are mild, so the toxic dose sits right on top of the felt one.
Resources
This entry is here for reference.
Research
- 1992first citedEvaluation of the neurotoxicity of N-methyl-1-(4-methoxyphenyl)-2-aminopropane (para-methoxymet…
- 2017most recentStudies on Para-Methoxymethamphetamine (PMMA) Metabolite Pattern and Influence of CYP2D6 Geneti…
- 1.Studies on distribution and metabolism of para-methoxymethamphetamine (PMMA) in rats after subcutaneous administration.
- 2.Potentiation of 3,4-methylenedioxymethamphetamine-induced 5-HT release in the rat substantia nigra by clorgyline, a monoamine oxidase A inhibitor.
- 3.Evaluation of the neurotoxicity of N-methyl-1-(4-methoxyphenyl)-2-aminopropane (para-methoxymethamphetamine, PMMA).
- 4.A fatal paramethoxymethamphetamine intoxication.
- 5.[Intoxation with paramethoxymethamphetamine].
- 6.Studies on Para-Methoxymethamphetamine (PMMA) Metabolite Pattern and Influence of CYP2D6 Genetics in Human Liver Microsomes and Authentic Samples from Fatal PMMA Intoxications.
- 7.Metabolism of designer drugs of abuse.
7 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
How is PMMA different from PMA?
PMMA has an added N-methyl group but behaves similarly; both are far more dangerous than MDMA and have caused deaths.
Why do deaths happen with it?
The slow onset leads people to take more, and its serotonin release with MAOI activity drives fatal overheating.
Is it common in ecstasy?
It has appeared in adulterated pills sold as MDMA, sometimes alongside PMA, which is why reagent testing matters.
Adverse effects
- Fatal hyperthermia risk
- Serotonin toxicity
- Cardiovascular strain and seizures
Notes and cautions
- Slow onset that promotes overdosing